First Coronavirus vaccine tested on human, Moderna, is showing promising early results
The first coronavirus vaccine to be tested in people appears to be safe and able to stimulate an immune response against the infection, the manufacturer, Moderna, announced Monday, offering a glint of hope to a world desperate for ways to stop the pandemic.
The preliminary findings, in the first eight people who each received two doses of the experimental vaccine, must now be repeated in far larger tests in hundreds and then thousands of people, to find out if the vaccine can work in the real world. Moderna’s technology, involving genetic material from the virus called mRNA, is relatively new and has yet to produce an approved vaccine.
The promising early news sent Moderna’s stock soaring by more than 25 percent on Monday afternoon and helped drive Wall Street to its best day in six weeks. Stocks were also lifted by statements from the Federal Reserve chair, Jerome H. Powell, that the central bank would continue to support the economy and markets.
Dozens of companies and universities are rushing to create coronavirus vaccines, and human trials have already started for several manufacturers, including Pfizer and its German partner BioNTech, the Chinese company CanSino and the University of Oxford, which is working with AstraZeneca.
Experts agree that it is essential to develop multiple vaccines because the urgent global need for billions of doses will far outstrip the production capacity of any one manufacturer. But there is widespread concern among scientists that haste could compromise the safety, resulting in a vaccine that does not work or even harms patients.
The potential strength of Moderna’s mRNA approach to vaccine making is that it uses a genetic framework that can be quickly adapted for each new viral threat. The company has said that it is proceeding on an accelerated timetable, with the second phase of tests involving 600 people to begin soon, and a third phase to begin in July involving thousands of healthy people. The Food and Drug Administration gave Moderna the go-ahead this month for the second phase.
If those trials go well, some doses of a vaccine could become available for widespread use by the end of this year or early 2021, Dr Tal Zaks, Moderna’s chief medical officer, said in an interview. “We’re doing our best to make it as many millions as possible.”
Denise Grady c.2020 The New York Times Company
Updated Date: May 19, 2020 17:27:55 IST
Tags : Antibody Tests, Clinical Trials, Coronavirus, Coronavirus Cases, Coronavirus Lockdown, Coronavirus Outbreak, Coronavirus Testing, Cure, Death Cases, Easing Lockdown Restrictions, Frontline Workers, Human Trials, Increase In Coronavirus Cases, Moderna, Pandemic, Testing, Treatment, Vaccine, WHO
Why social distancing is still the most effective non-pharmaceutical intervention for COVID-19
Studies suggest even mild symptoms of COVID-19 can cause severe damage to lungs, heart and brain
COVID-19 Treatment: Bemcentinib, Heparin and 3 other drugs to be tested by UK in their ACCORD programme
Hydroxychloroquine sustained dose and PPE can reduce COVID-19 risk in healthcare workers, ICMR study says
COVID-19 Testing: Gold nanoparticle-based test kit can give results within 10 minutes
New French study suggests 10% of diabetes patients who contract COVID-19 die within a week
Coronavirus Outbreak Updates: 2,091 people test positive for COVID-19 in Maharashtra today; confirmed cases rise to 54,758 in state
Coronavirus Outbreak Updates: 459 people test positive for COVID-19 in Pune today, total number of cases rises to 6,153
Coronavirus Outbreak Updates: Gujarat BJP MLA Balram Thawani tests positive for COVID-19; 423 new cases reported in state today
Coronavirus Outbreak Updates: Mumbai reports 1,382 new COVID-19 cases; confirmed infections rise to 25,317
Coronavirus Outbreak Updates: Junior assistant in Delhi LG's office tests positive for COVID-19; samples from 40 staff members taken
Coronavirus Outbreak Updates: Film producers' association writes to Uddhav Thackeray requesting resumption of film and TV shoots